Kensey Nash Corp. (KNSY) Enters Into Sales Agreement with Spectranetics
Kensey Nash Corp. (KNSY), a medical technology company that provides solutions and technologies for a variety of medical procedures, has entered into a definitive agreement with Spectranetics Corporation. Under the agreement, the company will sell its endovascular business, including the ThromCat™, QuickCat™ and Safecross™ products, to Spectranetics. Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in multiple, minimally invasive cardiovascular procedures. Kensey Nash will receive up to $24M consisting of a $10M initial cash payment, $8.0M in future product development milestone payments, and a $6.0M milestone associated with cumulative sales.…